Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
$327.38
-$0.21(-0.08%)
At close: 4:00 PM EST
$327.38
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$257.05 - $346.38
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.79M
Market Cap
$176.29B
Enterprise Value$198.09B
Total Cash (Recent Filing)$9.45B
Total Debt (Recent Filing)$54.59B
Price to Earnings (P/E)25.3
Beta0.37
Next Earnings
Feb 03, 2026EPS Estimate
4.73Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)5.64
Shares Outstanding538,480,650
10 Day Avg. Volume2,898,651
30 Day Avg. Volume2,792,207
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)23.99
Price to Sales (P/S)4.22
P/FCF Ratio13.57
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue5.51
Enterprise Value/Gross Profit8.33
Enterprise Value/Ebitda11.98
Forecast
1Y Price Target
$343.43Price Target Upside4.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)21.28
Revenue Forecast (FY)$36.34B
Bulls Say, Bears Say
Bulls Say
EarningsAmgen's third-quarter revenues came in at $9.6 billion, beating estimates and consensus of $9.0 billion.
Financial GuidanceAmgen raised 2025 revenue and EPS guidance, indicating confidence in future performance.
Product PerformanceRepatha revenue increased 40% year over year, reflecting strong efforts by Amgen and commercialization strategies turning it into a key growth driver.
Bears Say
Analyst RatingAnalyst reiterates an 'UNDERPERFORM' rating with a price objective of $272, which is below the current price.
Operational ChallengesAnalyst continues to model gradual operating margin erosion, reflecting ramped up obesity spending and generic erosion.
Valuation ConcernsAmgen is considered overvalued as it trades at a P/E multiple slightly above average.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $257.05 and its highest was $346.38 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $176.29B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Feb 03, 2026 which is in 44 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Nov 04, 2025. The company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.019 by $0.621.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 4.73.
How many shares outstanding does Amgen have?
Amgen has 538,480,650 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.64 in its last earnings report, beating expectations of $5.019. Following the earnings report the stock price went up 7.804%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$343.43 (4.90% Upside)
$343.43 (4.90% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 579.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.42%
12-Months-Change
Fundamentals
Return on Equity
81.71%
Trailing 12-Months
Asset Growth
-0.82%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong financial performance with a 12% revenue increase and significant volume growth driven by key products. There were notable advances in cardiovascular studies and the biosimilar portfolio, alongside new initiatives like AmgenNow to improve patient access. However, the call also highlighted challenges such as increased competition in certain segments, generic impacts on rare disease products, and some delays in study readouts. Overall, the positives in growth and strategic initiatives outweighed the negatives.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$343.43
▲(4.90% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
24.21% Mutual Funds
20.65% Other Institutional Investors
25.60% Public Companies and Individual Investors